Daniel Abate-Daga

Daniel Abate-Daga

Auto-generated profile, based on publicly available information

Daniel Abate-Daga

Moffitt Cancer Center 1 Department of Immunology Tampa, Florida

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Journal of Immunotherapy
Verified
Journal Article
Closed access
RMRichard A. Morgan
Richard A. Morgan
NCNachimuthu Chinnasamy
Nachimuthu Chinnasamy
DADaniel Abate-Daga
Daniel Abate-Daga
AGAlena Gros
Alena Gros
PRPaul F. Robbins
Paul F. Robbins
SRSteven A. Rosenberg
Steven A. Rosenberg
Nine cancer patients were treated with adoptive cell therapy using autologous anti-MAGE-A3 T-cell receptors (TCR)-engineered T cells. Five patients experienced clinical regression of their cancers including 2 on-going responders. Beginning 1–2 days postinfusion, 3 patients (#’s 5, 7, and 8) experienced mental status changes, and 2 patients (5 and 8) lapsed into comas and subsequently died. Magnetic resonance imagining analysis of patients 5 and 8 demonstrated periventricular leukomalacia, and examination of their brains at autopsy revealed necrotizing leukoencephalopathy with extensive white matter defects associated with infiltration of CD3+/CD8+ T cells. Patient 7, developed Parkinson-like symptoms, which resolved over 4 weeks and fully recovered. Immunohistochemical staining of patient and normal brain samples demonstrated rare positively staining neurons with an antibody that recognizes multiple MAGE-A family members. The TCR used in this study recognized epitopes in MAGE-A3/A9/A12. Molecular assays of human brain samples using real-time quantitative-polymerase chain reaction, Nanostring quantitation, and deep-sequencing indicated that MAGE-A12 was expressed in human brain (and possibly MAGE-A1, MAGE-A8, and MAGE-A9). This previously unrecognized expression of MAGE-A12 in human brain was possibly the initiating event of a TCR-mediated inflammatory response that resulted in neuronal cell destruction and raises caution for clinical applications targeting MAGE-A family members with highly active immunotherapies.

1 December 2014 in Human Gene Therapy
Verified
Journal Article
Closed access
DADaniel Abate-Daga
Daniel Abate-Daga
KLKiran H. Lagisetty
Kiran H. Lagisetty
ETEric Tran
Eric Tran
ZZZhili Zheng
Zhili Zheng
LGLuca Gattinoni
Luca Gattinoni
RMRichard A. Morgan
Richard A. Morgan
Despite advances in the understanding of its molecular pathophysiology, pancreatic cancer remains largely incurable, highlighting the need for novel therapies. We developed a chimeric antigen receptor (CAR) specific for prostate stem cell antigen (PSCA), a glycoprotein that is overexpressed in pancreatic cancer starting at early stages of malignant transformation. To optimize the CAR design, we used antigen-recognition domains derived from mouse or human antibodies, and intracellular signaling domains containing one or two T cell costimulatory elements, in addition to CD3zeta. Comparing multiple constructs established that the CAR based on human monoclonal antibody Ha1-4.117 had the greatest reactivity in vitro. To further analyze this CAR, we developed a human pancreatic cancer xenograft model and adoptively transferred CAR-engineered T cells into animals with established tumors. CAR-engineered human lymphocytes induced significant antitumor activity, and unlike what has been described for other CARs, a second-generation CAR (containing CD28 cosignaling domain) induced a more potent antitumor effect than a third-generation CAR (containing CD28 and 41BB cosignaling domains). While our results provide evidence to support PSCA as a target antigen for CAR-based immunotherapy of pancreatic cancer, the expression of PSCA on selected normal tissues could be a source of limiting toxicity.

1 January 2016 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
DADaniel Abate-Daga
Daniel Abate-Daga
MDMarco L Davila
Marco L Davila
MTO is an international, online-only, open-access journal focusing on the development and clinical testing of molecular therapies targeting cancer

1 June 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
DLDan Li
Dan Li
NLNan Li
Nan Li
YZYi-Fan Zhang
Yi-Fan Zhang
FHFu Haiying
Fu Haiying
MFMingqian Feng
Mingqian Feng
MHMitchell Ho
Mitchell Ho

12 February 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MRMaria C. Ramello
Maria C. Ramello
IBIsmahène Benzaïd
Ismahène Benzaïd
BKBrent M. Kuenzi
Brent M. Kuenzi
MLMaritza Lienlaf-Moreno
Maritza Lienlaf-Moreno
WKWendy M. Kandell
Wendy M. Kandell
DADaniel Abate-Daga
Daniel Abate-Daga
The total length of CAR intracellular domains determines interactions with endogenous proteins to promote TCR signaling.

20 September 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
GLGongbo Li
Gongbo Li
JBJustin C. Boucher
Justin C. Boucher
HKHiroshi Kotani
Hiroshi Kotani
KPKyungho Park
Kyungho Park
YZYongliang Zhang
Yongliang Zhang
MDMarco L. Davila
Marco L. Davila
Chimeric antigen receptors (CARs) have an antigen-binding domain fused to transmembrane, costimulatory, and CD3ζ domains. Two CARs with regulatory approval include a CD28 or 4-1BB costimulatory domain. While both CARs achieve similar clinical outcomes, biologic differences have become apparent but not completely understood. Therefore, in this study we aimed to identify mechanistic differences between 4-1BB and CD28 costimulation that contribute to the biologic differences between the 2 CARs and could be exploited to enhance CAR T cell function. Using CD19-targeted CAR T cells with 4-1BB we determined that enhancement of T cell function is driven by NF-κB. Comparison to CAR T cells with CD28 also revealed that 4-1BB is associated with more antiapoptotic proteins and dependence on persistence for B cell killing. While TNF receptor–associated factor 2 (TRAF2) has been presupposed to be required for 4-1BB costimulation in CAR T cells, we determined that TRAF1 and TRAF3 are also critical. We observed that TRAFs impacted CAR T viability and proliferation, as well as cytotoxicity and/or cytokines, in part by regulating NF-κB. Our study demonstrates how 4-1BB costimulation in CAR T cells impacts antitumor eradication and clinical outcomes and has implications for enhanced CAR design.